Debrisoquine hydroxylation phenotyping: do we expect too much?
作者信息
Mitchell S C, Haley C S
出版信息
Lancet. 1990 Sep 15;336(8716):694. doi: 10.1016/0140-6736(90)92193-l.
PMID:1975883
Abstract
摘要
相似文献
1
Debrisoquine hydroxylation phenotyping: do we expect too much?异喹胍羟基化表型分析：我们期望过高了吗？
Lancet. 1990 Sep 15;336(8716):694. doi: 10.1016/0140-6736(90)92193-l.
2
Diurnal effects on debrisoquine hydroxylation phenotyping.
Eur J Clin Pharmacol. 1988;35(4):441-2. doi: 10.1007/BF00561381.
3
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.芬兰人和拉普人中异喹胍羟基化的多态性。
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
4
Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
Lancet. 1984 Dec 15;2(8416):1393. doi: 10.1016/s0140-6736(84)92081-6.
5
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
6
Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.中国人中异喹胍4-羟化的多态性及慢代谢者的家系研究。
Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):7-10.
7
Debrisoquine hydroxylation polymorphism and personality.异喹胍羟基化多态性与人格
Lancet. 1989 Mar 11;1(8637):555. doi: 10.1016/s0140-6736(89)90094-9.
8
Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.地西泮治疗不影响异喹胍或美芬妥英羟化表型试验。
Ther Drug Monit. 1989 Nov;11(6):721-3. doi: 10.1097/00007691-198911000-00019.
9
Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.右美沙芬作为去甲丙咪嗪羟化多态性的安全探针。
Lancet. 1984 Sep 1;2(8401):517-8. doi: 10.1016/s0140-6736(84)92591-1.
10
Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.
Am Heart J. 1983 Jan;105(1):159-61. doi: 10.1016/0002-8703(83)90297-1.
Zotero 插件